Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 6/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 6/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 6/20 | 1.00 |
| ▸ | DRD1 | P21728 | 6/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 0.79 |
| ▸ | DRD3 | P35462 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmethylolanzapine SCHEMBL2183626 | 0.99 | DRD2 (0.98) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL28763 | 0.88 | CHRM1 (1.00) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29358280 | 0.88 | CHRM1 (1.00) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL4775632 | 0.88 | CHRM1 (1.00) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1376031 | 0.87 | CHRM1 (0.98) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1375329 | 0.87 | CHRM1 (0.98) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1562676 | 0.87 | CHRM1 (0.98) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL5091769 | 0.87 | CHRM1 (0.98) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL6461808 | 0.87 | CHRM1 (0.98) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL2222724 | 0.87 | CHRM1 (0.98) | DRD2CHRM1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102276592-B | Related substance of olanzapine and preparation method and analytical method thereof | UNIV DALIAN TECH | 2013-10-16 | — | — | CN | claimed |
| EP-1513845-B2 | A PROCESS FOR THE PREPARATION OF OLANZAPINE AND AN INTERMEDIATE THEREFOR | ADAMED SP ZOO (PL) | 2010-11-03 | — | — | EP | claimed |
| EP-1513845-B1 | A PROCESS FOR THE PREPARATION OF OLANZAPINE AND AN INTERMEDIATE THEREFOR | ADAMED SP ZOO (PL) | 2007-09-19 | — | — | EP | claimed |
| EP-1669359-B1 | A process for the preparation of olanzapine and an intermediate therefor | ADAMED SP ZOO (PL) | 2007-08-29 | — | — | EP | claimed |
| EP-1669359-A1 | A process for the preparation of olanzapine and an intermediate therefor | Adamed SP. Z O.O. (PL) | 2006-06-14 | — | — | EP | claimed |
| EP-1513845-A1 | A PROCESS FOR THE PREPARATION OF OLANZAPINE AND AN INTERMEDIATE THEREFOR | Adamed SP. Z O.O. (PL) | 2005-03-16 | — | — | EP | claimed |
| WO-2004000847-A1 | A PROCESS FOR THE PREPARATION OF OLANZAPINE AND AN INTERMEDIATE THEREFOR | ADAMED SP. Z O.O. (PL) | 2003-12-31 | — | — | WO | claimed |
| US-11518755-B2 | Stable solutions of multicyclic antidepressants | LEYDEN TECHNOLOGIES B.V. (NL) | 2022-12-06 | — | — | US | disclosed |
| US-11193925-B2 | Medication adherence monitoring device | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200290999-A1 | Stable solutions of multicyclic antidepressants | LEYDEN TECHNOLOGIES B.V. (NL) | 2020-09-17 | — | — | US | disclosed |
| WO-2019068859-A1 | STABLE SOLUTIONS OF MULTICYCLIC ANTIDEPRESSANTS | LEYDEN TECHNOLOGIES B.V. (NL) | 2019-04-11 | — | — | WO | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-2956456-B1 | A PROCESS FOR PREPARATION OF OLANZAPINE PAMOATE | NEULAND LABORATORIES LTD (IN) | 2017-07-12 | — | — | EP | disclosed |
| WO-2004000847-A1 | A PROCESS FOR THE PREPARATION OF OLANZAPINE AND AN INTERMEDIATE THEREFOR | ADAMED SP. Z O.O. (PL) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000847-A1 | A PROCESS FOR THE PREPARATION OF OLANZAPINE AND AN INTERMEDIATE THEREFOR | ADAMED SP. Z O.O. (PL) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000847-A1 | A PROCESS FOR THE PREPARATION OF OLANZAPINE AND AN INTERMEDIATE THEREFOR | ADAMED SP. Z O.O. (PL) | 2003-12-31 | — | — | WO | disclosed |
| US-6468997-B2 | ACTIVE METABOLITE OF OLANZAPINE; FOR THE TREATMENT OF PSYCHOSIS IN HUMANS; CO-ADMINISTRATION WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS; FEWER DRUG INTERACTIONS AND MORE STABLE DOSING THAN PARENT DRUG | SEPRACOR INC. | 2002-10-22 | — | — | US | disclosed |
| US-6348455-B1 | COMPOUND FOR TREATMENT OF PSYCHOSIS | SEPRACOR INC. | 2002-02-19 | — | — | US | disclosed |
| EP-1133300-A1 | DESMETHYLOLANZAPINE COMPOSITIONS AND METHODS | Sepracor Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000030650-A1 | DESMETHYLOLANZAPINE COMPOSITIONS AND METHODS | SEPRACOR INC. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518755-B2 | Stable solutions of multicyclic antidepressants | TPH1, BDNF, TPH2 | DRD2 27/4885CHRM1 217/4885CHRM2 159/4885 |
| US-20200290999-A1 | Stable solutions of multicyclic antidepressants | TPH1, BDNF, TPH2 | DRD2 27/4885CHRM1 217/4885CHRM2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.